GREGORY LUNCEFORD: Open Payments
NPI 1851373047 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$681 in 34 payments from 8 companies in 2025. Trend: 2023 $629 · 2024 $819 · 2025 $681
Food & beverage: $681
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $182 |
| ABBVIE INC. | 12 | $150 |
| E.R. Squibb & Sons, L.L.C. | 4 | $94 |
| Neurocrine BioSciences, Inc. | 3 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Alkermes, Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Tris Pharma Inc | 1 | $20 |
Products named: VRAYLAR, AUSTEDO XR, COBENFY, INGREZZA, ARISTADA, UZEDY, REXULTI, CAPLYTA.
Industry payments across GA — which companies pay providers there.
